Developer docs
API playgroundTry for free, no card

Search company profiles

Catalyst Clinical Research

Full company profile

uuid0003oo5

Namestring
Catalyst Clinical Research
Websiteurl
catalystcr.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Catalyst Clinical Research was a specialized oncology contract research organization (CRO) founded in 2013 and headquartered in Wilmington, North Carolina. The company provided clinical development services to pharmaceutical and biotechnology companies, focused on early-phase oncology trials, cell and gene therapy development, and rare disease research. Prior to its February 2026 acquisition by Worldwide Clinical Trials, Catalyst was privately held and backed by private equity firm QHP Capital. Customers were enterprise pharmaceutical and biotechnology companies conducting oncology drug development programs.

Short descriptiontext

Catalyst Clinical Research was a privately held oncology-focused contract research organization providing early-phase clinical trial services, cell and gene therapy research, and rare disease studies to pharmaceutical and biotechnology companies through FSP and full-service models.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWilmington, United States
HQ citystring
Wilmington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology clinical research, contract research organization, early phase trials, functional service provider, cell and gene therapy
Industry4 codes
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAOAA
Clinical Operations & Monitoring FSP (CRA/CTM/Start-up)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Organization (Clinical Research Services)
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Research Services
TypeProfessional Services
Description

Catalyst generated revenue by providing contract clinical research services to pharmaceutical and biotechnology companies conducting oncology clinical trials. Services included early-phase oncology studies, clinical operations, biometrics, and functional service provision under fee-for-service and FSP arrangements.

catalystcr.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom clinical research service engagements
ModelOtherBilling cadenceMulti-year contract
Notes

Fee-for-service and FSP (Functional Service Provider) pricing models tailored to individual client study requirements, scope, and duration.

catalystcr.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Catalyst Clinical Research is a specialized oncology contract research organization (CRO) that delivers clinical trial services to pharmaceutical and biotechnology companies. Core offerings include early-phase oncology studies, full-service oncology clinical research, cell and gene therapy programs, rare disease research, biometrics, and a flexible Functional Service Provider (FSP) engagement model enabling clients to scale clinical operations support on a customized basis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • More than 100 active oncology studies at time of Aptus acquisition (2022)
+1 more record
Product overview1 text field

Catalyst Clinical Research operated as a specialized oncology contract research organization (CRO) offering a platform of clinical development services. The core offerings included early-phase oncology expertise and a Functional Service Provider (FSP) model, supplemented by acquired capabilities from Genpro Research (global operations in US, India, Ireland) and Aptus Clinical (European expertise in oncology, cell and gene therapies, and rare diseases). The company engaged in more than 100 active oncology studies at the time of its acquisition by Worldwide Clinical Trials in Q1 2026.

Product and service5 records
1Early Phase Oncology Services
CategoryEarly-phase oncology clinical research
Description

Specialized contract research services for early-phase oncology clinical trials, including Phase I and proof-of-concept studies, delivered to pharmaceutical and biotechnology sponsors developing oncology therapeutics.

2Functional Service Provider (FSP) Model
CategoryFunctional service provision
Description

Flexible FSP engagement model allowing pharmaceutical and biotechnology sponsors to access specialized clinical research functions (biometrics, clinical operations, data management, etc.) on a scalable, customizable basis.

3Oncology Clinical Research
CategoryOncology clinical trial management
Description

Full-service oncology clinical trial management covering multiple cancer types including solid tumors and hematologic malignancies, provided to pharmaceutical and biotechnology sponsors.

4Cell and Gene Therapy Services
CategoryCell and gene therapy clinical research
Description

Specialized clinical research services for cell and gene therapy development programs, delivered to pharmaceutical and biotechnology sponsors in oncology and rare disease indications.

5Rare Disease Research
CategoryRare disease clinical research
Description

Clinical research services focused on rare oncology indications and rare diseases, delivered to pharmaceutical and biotechnology sponsors.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeOthersAnnounced on2026-02-16
Description

Worldwide Clinical Trials completed acquisition of Catalyst Clinical Research in February 2026. The transaction integrated Catalyst's early-phase oncology expertise and FSP model with Worldwide's late-phase development and CNS capabilities, creating a combined organization operating across more than 70 countries with approximately 4,400 employees.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-20
Description

Catalyst Clinical Research acquired Genpro Research, a global clinical research organization with operations in the US, India, and Ireland. This acquisition expanded Catalyst's global footprint and operational capabilities.

3Aptus Clinical
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-04
Description

Catalyst acquired Aptus Clinical to expand its presence in Europe and enhance clinical research services in oncology, cell and gene therapies, and rare diseases. The combined entity aimed to accelerate growth in the US and Europe.

catalystcr.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Mid-to-large global CRO with a strong oncology franchise and therapeutic-area-aligned operating model; competes head-to-head with Catalyst for oncology clinical trial work from pharma and biotech sponsors.

TypeDirect peer
Description

Global CRO with deep oncology, neuroscience, and rare disease expertise that acquired Catalyst in February 2026; the acquirer and now parent, operating the combined platform.

TypeDirect peer
Description

Specialty CRO with a strong oncology and rare disease focus, including a dedicated FSP offering; competes with Catalyst for early-phase oncology and rare-disease trial work.

TypeEmerging player
Description

Specialty oncology CRO focused on early-phase and translational drug development; competes with Catalyst for early-phase oncology studies from biotech sponsors.

TypeBroad incumbent
Description

Oncology-focused CRO that was acquired by IQVIA; continues to compete in the oncology specialty space as part of IQVIA's broader clinical services portfolio.

TypeBroad incumbent
Description

Top-tier global CRO offering full-service clinical development including oncology; competes with Catalyst for large pharma oncology programs.

TypeBroad incumbent
Description

Largest global CRO with extensive oncology capabilities; competes with Catalyst across the full oncology trial lifecycle, especially for large pharma mega-programs.

TypeBroad incumbent
Description

Global CRO with established oncology and rare disease capabilities; competes with Catalyst for full-service and FSP oncology engagements with pharma and biotech.

TypeBroad incumbent
Description

Major global CRO with broad oncology and central laboratory capabilities; competes with Catalyst in oncology clinical trial execution and biomarker testing.

TypeEmerging player
Description

Specialty CRO focused on oncology and rare disease clinical trials with biomarker and laboratory services; directly overlaps with Catalyst's oncology and rare-disease offerings.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Catalyst Clinical Research

Contract Research Organization (Clinical Research Services)catalystcr.com

Catalyst Clinical Research was a privately held oncology-focused contract research organization providing early-phase clinical trial services, cell and gene therapy research, and rare disease studies to pharmaceutical and biotechnology companies through FSP and full-service models.

What Catalyst Clinical Research does

Catalyst Clinical Research was a specialized oncology contract research organization (CRO) founded in 2013 and headquartered in Wilmington, North Carolina. The company provided clinical development services to pharmaceutical and biotechnology companies, focused on early-phase oncology trials, cell and gene therapy development, and rare disease research. Prior to its February 2026 acquisition by Worldwide Clinical Trials, Catalyst was privately held and backed by private equity firm QHP Capital. Customers were enterprise pharmaceutical and biotechnology companies conducting oncology drug development programs.

Catalyst Clinical Research firmographics

Firmographics
Name
Catalyst Clinical Research
Website
https://catalystcr.com
Company type
Private
Founded year
2013
Operating status
Acquired
Headcount range
101–250 employees
Short description
Catalyst Clinical Research was a privately held oncology-focused contract research organization providing early-phase clinical trial services, cell and gene therapy research, and rare disease studies to pharmaceutical and biotechnology companies through FSP and full-service models.
Ownership category
akta.pro rank

Catalyst Clinical Research industry classification

Industry
Product category
Contract Research Organization (Clinical Research Services)
NAICS
Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAOAA
Clinical Operations & Monitoring FSP (CRA/CTM/Start-up)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
SECONDARYHLAGAAAI
Patient Recruitment, Site Feasibility & Trial Enablement CROs

Keywords

  • Oncology clinical research
  • Contract research organization
  • Early phase trials
  • Functional service provider
  • Cell and gene therapy

Where Catalyst Clinical Research is headquartered

Location

Headquarters

HQ city
Wilmington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Catalyst Clinical Research business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Research Services: Catalyst generated revenue by providing contract clinical research services to pharmaceutical and biotechnology companies conducting oncology clinical trials. Services included early-phase oncology studies, clinical operations, biometrics, and functional service provision under fee-for-service and FSP arrangements.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom clinical research service engagements

Go-to-market motion2 records

Distribution channels1 record

Marketing channels1 record

Catalyst Clinical Research product offering

Product offering

Core offering

Catalyst Clinical Research is a specialized oncology contract research organization (CRO) that delivers clinical trial services to pharmaceutical and biotechnology companies. Core offerings include early-phase oncology studies, full-service oncology clinical research, cell and gene therapy programs, rare disease research, biometrics, and a flexible Functional Service Provider (FSP) engagement model enabling clients to scale clinical operations support on a customized basis.

Product overview

Catalyst Clinical Research operated as a specialized oncology contract research organization (CRO) offering a platform of clinical development services. The core offerings included early-phase oncology expertise and a Functional Service Provider (FSP) model, supplemented by acquired capabilities from Genpro Research (global operations in US, India, Ireland) and Aptus Clinical (European expertise in oncology, cell and gene therapies, and rare diseases). The company engaged in more than 100 active oncology studies at the time of its acquisition by Worldwide Clinical Trials in Q1 2026.

Differentiator

Problem solved

Functional benefit

Products and services

  • Early Phase Oncology Services Specialized contract research services for early-phase oncology clinical trials, including Phase I and proof-of-concept studies, delivered to pharmaceutical and biotechnology sponsors developing oncology therapeutics.
  • Functional Service Provider (FSP) Model Flexible FSP engagement model allowing pharmaceutical and biotechnology sponsors to access specialized clinical research functions (biometrics, clinical operations, data management, etc.) on a scalable, customizable basis.
  • Oncology Clinical Research Full-service oncology clinical trial management covering multiple cancer types including solid tumors and hematologic malignancies, provided to pharmaceutical and biotechnology sponsors.
  • Cell and Gene Therapy Services Specialized clinical research services for cell and gene therapy development programs, delivered to pharmaceutical and biotechnology sponsors in oncology and rare disease indications.
  • Rare Disease Research Clinical research services focused on rare oncology indications and rare diseases, delivered to pharmaceutical and biotechnology sponsors.

Quantifiable outcome

  • More than 100 active oncology studies at time of Aptus acquisition (2022)
  • +1 more outcomes

Companies that use Catalyst Clinical Research

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Catalyst Clinical Research technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Catalyst Clinical Research partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Worldwide Clinical TrialscoreOthers · 16 February 2026Worldwide Clinical Trials completed acquisition of Catalyst Clinical Research in February 2026. The transaction integrated Catalyst's early-phase oncology expertise and FSP model with Worldwide's late-phase development and CNS capabilities, creating a combined organization operating across more than 70 countries with approximately 4,400 employees.
  • Genpro ResearchcoreStrategic or Co-development Partner · 20 July 2023Catalyst Clinical Research acquired Genpro Research, a global clinical research organization with operations in the US, India, and Ireland. This acquisition expanded Catalyst's global footprint and operational capabilities.
  • Aptus ClinicalcoreStrategic or Co-development Partner · 4 May 2022Catalyst acquired Aptus Clinical to expand its presence in Europe and enhance clinical research services in oncology, cell and gene therapies, and rare diseases. The combined entity aimed to accelerate growth in the US and Europe.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Catalyst Clinical Research competitors and assessment

Company assessment

Direct peers

  • Medpace: Mid-to-large global CRO with a strong oncology franchise and therapeutic-area-aligned operating model; competes head-to-head with Catalyst for oncology clinical trial work from pharma and biotech sponsors.
  • Worldwide Clinical Trials: Global CRO with deep oncology, neuroscience, and rare disease expertise that acquired Catalyst in February 2026; the acquirer and now parent, operating the combined platform.
  • Ergomed: Specialty CRO with a strong oncology and rare disease focus, including a dedicated FSP offering; competes with Catalyst for early-phase oncology and rare-disease trial work.

Emerging players

  • Translational Drug Development (TD2): Specialty oncology CRO focused on early-phase and translational drug development; competes with Catalyst for early-phase oncology studies from biotech sponsors.
  • Precision for Medicine: Specialty CRO focused on oncology and rare disease clinical trials with biomarker and laboratory services; directly overlaps with Catalyst's oncology and rare-disease offerings.

Broad incumbents

  • Novella Clinical (IQVIA): Oncology-focused CRO that was acquired by IQVIA; continues to compete in the oncology specialty space as part of IQVIA's broader clinical services portfolio.
  • ICON plc: Top-tier global CRO offering full-service clinical development including oncology; competes with Catalyst for large pharma oncology programs.
  • IQVIA: Largest global CRO with extensive oncology capabilities; competes with Catalyst across the full oncology trial lifecycle, especially for large pharma mega-programs.
  • Parexel: Global CRO with established oncology and rare disease capabilities; competes with Catalyst for full-service and FSP oncology engagements with pharma and biotech.
  • Labcorp Drug Development (formerly Covance): Major global CRO with broad oncology and central laboratory capabilities; competes with Catalyst in oncology clinical trial execution and biomarker testing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Catalyst Clinical Research social profiles

Digital presence

Catalyst Clinical Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Catalyst Clinical Research leadership team

Management profile

Number of profiles

Profiles2 records

Catalyst Clinical Research subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Catalyst Clinical Research funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Catalyst Clinical Research M&A and investment

M&A and investment

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Catalyst Clinical Research

What does Catalyst Clinical Research do?

Catalyst Clinical Research is a specialized oncology contract research organization (CRO) that delivers clinical trial services to pharmaceutical and biotechnology companies. Core offerings include early-phase oncology studies, full-service oncology clinical research, cell and gene therapy programs, rare disease research, biometrics, and a flexible Functional Service Provider (FSP) engagement model enabling clients to scale clinical operations support on a customized basis.

Is Catalyst Clinical Research a public or private company?

Catalyst Clinical Research is a private company. It is classified as corporate owned and is currently acquired.

When was Catalyst Clinical Research founded?

Catalyst Clinical Research was founded in 2013. It employs 101 to 250 people.

Where is Catalyst Clinical Research based?

Catalyst Clinical Research is headquartered in Wilmington, United States, in the North America region.

How does Catalyst Clinical Research make money?

One revenue line is on record: clinical Research Services.

Who are Catalyst Clinical Research's main competitors?

Direct peers on record are Medpace, Worldwide Clinical Trials and Ergomed. Emerging players are Translational Drug Development (TD2) and Precision for Medicine. Broad incumbents are Novella Clinical (IQVIA), ICON plc, IQVIA, Parexel and Labcorp Drug Development (formerly Covance).

Does Catalyst Clinical Research have an API?

No public API is recorded for Catalyst Clinical Research.

What industry is Catalyst Clinical Research in?

Catalyst Clinical Research's product category is Contract Research Organization (Clinical Research Services). Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comUnited States Contract Research Organization Market 2026 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment OpportunitiesThe United States Contract Research Organization market was valued at US$59.9 billion in 2021 and is projected to reach US$170.4 billion by 2031, growing at a 13.58% CAGR during the forecast period (2024-2031). Key industry developments include MMS Holdings' acquisition of Exploristics (February 2026), Worldwide Clinical Trials' acquisition of Catalyst Clinical Research (January 2026), and Thermo Fisher Scientific's planned acquisition of Clario (December 2025), alongside increased private equity funding for CRO platforms. The global CRO market features major players including IQVIA Holdings, Labcorp Drug Development, PPD Inc., Parexel, and Charles River Laboratories International, with North America holding a 38% market share.Pulse 2.0Worldwide Clinical Trials Completes Acquisition Of Oncology Specialist Catalyst Clinical ResearchWorldwide Clinical Trials has completed its acquisition of oncology specialist Catalyst Clinical Research, expanding its capabilities in early-phase oncology, biometrics, and functional service provision. The transaction creates a combined organization of approximately 4,400 employees operating across more than 70 countries, with complementary strengths spanning oncology, biometrics, and functional services. Key executives from Catalyst have joined Worldwide's leadership team as part of the integration.MorningstarWorldwide Clinical Trials Completes Acquisition of Catalyst Clinical ResearchWorldwide Clinical Trials has completed its acquisition of Catalyst Clinical Research, a specialized oncology contract research organization. The combined organization now employs approximately 4,400 professionals across more than 70 countries, with expanded capabilities in oncology, biometrics, and functional service provider offerings. The transaction, for which the amount was undisclosed, was facilitated by private equity firms Kohlberg (majority owner of Worldwide) and QHP Capital (previous owner of Catalyst).Applied Clinical TrialsWorldwide Clinical Trials to Acquire Catalyst Clinical Research, Expanding Oncology and FSP CapabilitiesWorldwide Clinical Trials agreed to acquire Catalyst Clinical Research, an oncology-focused CRO, to strengthen oncology expertise and expand functional service provider offerings. The deal combines Catalyst's early-phase oncology and biometrics with Worldwide's late-phase and CNS strengths, with an expected closing in Q1 2026.Healthcare IT TodayWorldwide Clinical Trials Enters Definitive Agreement to Acquire Catalyst Clinical ResearchWorldwide Clinical Trials, a global contract research organization (CRO), has entered into a definitive agreement to acquire Catalyst Clinical Research, a specialized oncology CRO, for an undisclosed amount, with the transaction expected to close in 2026. The combination creates a leading oncology-focused CRO by integrating Catalyst's early phase oncology expertise and Functional Service Provider (FSP) model with Worldwide's CNS specialist capabilities, while adding Catalyst's leadership including Nick Dyer to Worldwide's Board and Nik Morton to its executive team. Separately, Net Health announced its acquisition of Keet Health from WebPT as part of a strategic collaboration to advance outcomes measurement and remote therapeutic monitoring for rehabilitation therapy providers, with an integrated experience targeted for early 2026.American City Business JournalsWorldwide Clinical Trials to acquire Catalyst Clinical ResearchWorldwide Clinical Trials announced its plan to acquire Catalyst Clinical Research. The article does not specify the date or the strategic implications of the acquisition.Business Wire BlogWorldwide Clinical Trials Enters Definitive Agreement to Acquire Catalyst Clinical ResearchWorldwide Clinical Trials has entered into a definitive agreement to acquire Catalyst Clinical Research, a specialized oncology contract research organization, with the transaction expected to close in Q1 2026 pending regulatory approvals. The strategic combination establishes Worldwide as a leading oncology-focused CRO by integrating Catalyst's early-phase oncology expertise and flexible FSP resourcing model with Worldwide's global footprint spanning over 60 countries. The deal terms remain undisclosed, and both companies will retain their respective leadership, with Catalyst's CEO joining Worldwide's executive team.WorldwideWorldwide Clinical Trials Enters Definitive Agreement to Acquire Catalyst Clinical ResearchWorldwide Clinical Trials, a global contract research organization, has entered into a definitive agreement to acquire Catalyst Clinical Research, a specialized oncology CRO, for an undisclosed amount. The strategic combination will establish Worldwide as a leading oncology-focused CRO by integrating Catalyst's early phase oncology expertise and its established FSP model with Worldwide's late-phase development capabilities. The transaction, expected to close in Q1 2026 subject to regulatory approvals, will bring together over 4,500 combined staff across the United States, Europe, and Asia-Pacific, with both companies maintaining their respective private equity backing from Kohlberg and QHP Capital.ContractpharmaWorldwide Clinical Trials to Acquire Catalyst Clinical ResearchWorldwide Clinical Trials is acquiring Catalyst Clinical Research, a specialized oncology CRO, in a strategic move to strengthen its focus on oncology and expand its global presence. The deal aims to enhance capabilities across multiple therapeutic areas and improve operational excellence using advanced tools and AI.